Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer
- 17k Downloads
Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific cell membrane marker for endothelial cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting(s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed.
KeywordsCD105 Human Umbilical Vein Endothelial Cell Hereditary Hemorrhagic Telangiectasia CD105 Promoter Vascular Target
activin receptor-like kinase
conditionally replicating adenoviruses
endothelial nitric oxide synthase
human umbilical vein endothelial cells
transforming growth factor
The availability of new and more sophisticated technologies, together with the improved knowledge on tumor-host interactions, have allowed the identification and characterization of different tumor-associated antigens (TAA) to be used as molecular targets for immunotherapeutic approaches in patients with solid or hematologic malignancies. Prompted by encouraging pre-clinical evidences, significant clinical results in cancer treatment have been obtained through antibody-based therapeutic regimens, such as those that target CD20 on malignant B cells  or HER2 in breast cancer . However, due to the heterogeneous expression of TAA in neoplastic tissues, these approaches raise some critical issues such as "patients' eligibility" to specific TAA-based treatment modalities. Moreover, the efficacy of TAA targeting is frequently limited by the inadequate accessibility of therapeutic antibodies or their derived molecules within the tumor mass .
Currently, great interest is focused on angiogenesis and on its potential clinical implications in cancer, and vascular targeting represents a highly promising alternative to the direct engagement of therapeutic TAA on neoplastic cells [4, 5]. Among potential therapeutic strategies to induce tumor regression by blocking tumor blood supply, an intriguing approach relies on the selective targeting of cell surface molecules over-expressed on endothelial cells of tumor-associated blood vessels [4, 5]. In this setting, emerging in vitro and in vivo pre-clinical evidence identifies CD105 as a cell membrane glycoprotein representing a prime vascular target to implement innovative antibody-based diagnostic and therapeutic strategies shared by human neoplasia of different histotype.
Biological features of CD105
In vivo distribution of CD105 on non-endothelial cells.
Early B cells
Follicular dendritic cells
Heart mesenchimal cells
Vascular smooth muscle cells
In solid neoplasia, CD105 is present on endothelial cells of both peri- and intra-tumoral blood vessels and on tumor stromal components [11, 17, 22, 23, 24]. In particular, CD105 is largely expressed in small and likely immature tumor vessels as demonstrated in breast, prostate and gastric cancer [24, 25, 26]; rarely, CD105 is expressed in the cytoplasm of neoplastic cells . In lung carcinoma, staining for CD105 was reported to be strong at the areas of active angiogenesis including tumor edge, while it was less intense in the central area of the tumor and not detectable in the adjacent normal tissue .
CD105 is a component of the receptor complex of Transforming Growth Factor (TGF)-β [27, 28, 29], a pleiotropic cytokine involved in cellular proliferation, differentiation and migration . It binds several components of the TGF-β superfamily [27, 29]. Interestingly, binding of TGF-β1 to CD105 reduces the levels of CD105 phosphorylation  and the levels of CD105 expression modulate the effects of TGF-β1 [28, 31, 32, 33, 34, 35]. In this respect, it is of interest that the inhibition of CD105 expression enhanced the ability of TGF-β1 to suppress growth, migration and capacity to form capillary tubes of cultured endothelial cells .
In the absence of TGF-β1, CD105 shows an anti-apoptotic effect in endothelial cells under hypoxic stress, suggesting for a protective role of CD105 against pro-apoptotic factors .
In addition, the discovery that levels of CD105 regulate the expression of different components of the extracellular matrix including fibronectin, collagen, PAI-1 and lumican [34, 37, 38], is also suggestive for a crucial role of CD105 in cellular transmigration .
Different environmental factors and cytokines involved in angiogenesis modulate CD105 expression. The levels of CD105 protein, mRNA and promoter activity are up-regulated by hypoxia  and by TGF-β1 [28, 39, 40, 41], which cooperate to induce the expression of CD105 at transcriptional level . Instead, TNF-α down-regulates CD105 protein levels but it has no effect at the transcriptional level .
Furthermore, CD105 expression was up-regulated on human umbilical vein endothelial cells (HUVEC) infected with a recombinant adenovirus carrying a constitutively active form of activin receptor-like kinase (ALK)-1, a type I TGF-β receptor .
Supporting the in vivo modulation of CD105 by pro-angiogenetic stimuli, elevated levels of CD105 were associated with high levels of vascular endothelial growth factor in non-small cell lung cancer lesions positive for angiopoietin-2, a regulatory factor of survival of endothelial cells, considerably expressed at sites of vascular remodelling and in highly vascularized tumors .
CD105 and vascularization
Even if its functional role is not fully understood, several findings suggest for the involvement of CD105 in angiogenesis and vascular development, and in maintaining vessel wall integrity.
First, CD105 expression is up-regulated on proliferating endothelial cells in culture [11, 12, 13] and on endothelial cells of angiogenetic blood vessels [11, 12, 24, 33, 45]. Furthermore, CD105 knockout mice died of defective vascular development during early gestation , as observed in TGF-β1- and ALK-1-null mice [47, 48]. In particular, CD105 null mice showed important structural defects in the primitive vascular plexus of the yolk sac that prevented the formation of normal mature vessels . Additionally, both in humans and mice, CD105 gene mutations are associated with hereditary hemorrhagic telangiectasia type 1, an inherited disease characterized by arteriovenous malformations and bleedings [49, 50, 51]. Finally, CD105 has been most recently suggested as a regulator factor of nitric oxide-dependent vasodilatation. In fact, the levels of CD105 expression modulated the amounts of endothelial nitric oxide synthase (eNOS) in kidney and femoral arteries of mice. Furthermore, over-expression or suppression of CD105 in cultured endothelial cells induced a marked increase or decrease in the protein levels of eNOS, respectively .
Intra-tumor microvessel density determined by immunohistochemical staining for CD105: an indicator of poor prognosis in patients with solid neoplasia.
Nonseminomatous testicular germ cell tumors
Non-small cell lung cancer
Renal cell carcinoma
Squamous cell carcinoma of the oral cavity
CD105 as a marker of survival in patients with solid tumors of different histotype.
CD105-MVDa correlation with survival
The number of CD105-positive microvessels correlated significantly (p = 0.001) with poor overall survival.
Patients with CD105-MVD above the median showed the worst prognosis; similar results were obtained when CD105-MVD was divided in quartiles.
Patients with the lower quartiles for CD105-MVD showed reduced survival compared to those with the higher quartiles.
Non-small cell lung cancer
5-year survival rate of patients with the lower CD105-MVD was higher compared to that of patients with the higher CD105-MVD.
Median survival time were shorter for patients with CD105-MVD above the median.
mAb directed to CD105 but not to the pan-endothelial marker CD34 revealed an inverse correlation between intra-tumoral microvessel density and apoptotic index of neoplastic cells in non-small cell lung cancer patients . Since angiogenesis is crucial for tumor development and progression , this finding provided supportive evidence to the usefulness of CD105 targeting in antiangiogenetic therapy of cancer .
Ex vivo background
Selected anti-CD105 monoclonal antibodies (mAb) significantly inhibit the proliferation of cultured human microvascular and macrovascular endothelial cells [11, 58, 59], thus supporting the notion that CD105 is a promising vascular target to implement innovative antibody-based therapeutic strategies in human cancer. Noteworthy, differences in the growth suppression of endothelial cells have been found among 4 anti-CD105 mAb defining different epitopes ; nevertheless, TGF-β1 and each of the 4 anti-CD105 mAb showed synergistic suppression of HUVEC proliferation .
A bispecific single-chain diabody directed to the adenovirus fiber knob domain and to CD105 was shown to be effective in enhancing adenovirus transduction in HUVEC, thus sustaining the use of CD105 protein as target for therapeutic gene transfer in endothelial cells . Along this line, a vector constructed with the CD105 promoter was efficiently utilized to deliver gene expression specifically to endothelial cells of mouse blood vessels . Additionally, human CD105 promoter fragments were successfully utilized in pigs to drive CD59 expression in the small vessels of heart, kidney and lung, but not in the large vessels of these organs .
Most recently, another bispecific single-chain diabody was proposed for therapeutic approaches aiming to destroy tumor-associated vasculature. This engineered antibody is directed to human CD105 as well as CD3 and it is effective to mediate killing of CD105-positive endothelial cells by cytotoxic T lymphocytes . An alternative strategy of CD105 targeting for anti-angiogenetic treatment of cancer might derive by the use of conditionally replicating adenoviruses (CRAD). In fact, CRAD obtained by utilizing Flk-1 and CD105 regulatory elements have been transcriptionally targeted towards proliferating endothelial cells, with specificity and efficacy in killing HUVEC .
In vivo diagnostic targeting
The over-expression of CD105 on proliferating endothelial cells of the tumour vasculature suggested that CD105 might also represent a good target for the immunoscintigraphy of tumors. In keeping with this idea, targeting of CD105 by radiolabeled mAb was described as a safe and effective procedure to image tumors in animal models [13, 65]. The intravenous administration of a 125I-labeled anti-CD105 mAb efficiently imaged spontaneous mammary adenocarcinomas in dogs. The immunoscintigraphy performed 8 hours after mAb injection demonstrated that the uptake of the radiolabeled mAb was rapid and intense, and no systemic side effects were observed in the injected dogs during a 3 months follow-up after imaging procedures . Consistently, the scintigraphy performed 15 minutes after administration of low doses of 111In-labeled anti-CD105 mAb in C57BL/6 mice demonstrated an accumulation of radioactivity in xenografts of human melanoma. The autoradiography and immunohistology showed a marked concentration of the mAb in the periphery of the tumor mass with an heterogeneous distribution in its centre. Noteworthy, the 97% of the injected dose of the radiolabeled anti-CD105 mAb was removed from the circulation within 15 min, and the blood half-life of the anti-CD105 mAb was estimated to be <1 minute .
The immunoscintigraphy performed after renal artery perfusion of 99Tcm-labeled anti-CD105 mAb in the freshly excised kidney from a patient with renal carcinoma identified 2 distinct hot spots of radioactivity, which matched the positions of the tumors, as demonstrated by the subsequent histopathologic examination; noteworthy, only one of the two tumor masses was identified by a pre-surgery magnetic resonance imaging scan .
In vivo therapeutic targeting
Targeting of CD105, as therapeutic antiangiogenetic approach in cancer, has been extensively investigated in severe combined immunodeficiency [SCID] mice bearing human breast tumors. The results of these studies demonstrated a long lasting suppression of tumor growth and metastasis by systemic administration of radiolabeled or immunotoxin-conjugated anti-CD105 mAb [67, 68, 69]. Furthermore, naked anti-CD105 mAb, which reacted strongly with proliferating human endothelial cells but weakly with murine endothelial cells, showed synergism with conventional chemotherapeutic regimens in a human skin/SCID mouse chimera model . Interestingly, in all these animal models the anti-tumor efficacy and the anti-metastatic activities were identified in the ability of the anti-CD105 mAb to inhibit tumor-associated angiogenesis and/or to obliterate tumor-associated vasculature [67, 68, 69, 70].
Conclusions and future directions
A number of convincing experimental findings suggest that selected anti-CD105 mAb can strongly localize to the endothelium of tumor-associated vasculature and that they are efficient to inhibit tumor angiogenesis, tumor growth and metastasis in mice, pointing to CD105 as a suitable vascular target to implement antibody-based therapeutic approaches in cancer.
However, concern about the therapeutic applications of anti-CD105 mAb and their derived molecules in cancer patients emerged by discrepancies observed in the expression of CD105 within normal and tumor tissues [71, 72, 73, 74]. In this respect, it has been suggested that not all anti-CD105 mAb are useful for anti-angiogenetic targeting since different mAb have different reactivity with the vasculature of normal tissues [45, 59, 66, 73]. Based on these findings, the comparative evaluation of the reactivity of a large panel of anti-CD105 mAb in the same tumor specimen has been proposed to identify the most reactive with tumor endothelium .
Nevertheless, the information on CD105 so far obtained by ex vivo studies and in animal models warrants additional efforts to further define the most appropriate therapeutic setting [s] for CD105 in human cancer, and to translate pre-clinical evidences into phase I/II clinical trials.
This work was supported in part by the Associazione Italiana per la Ricerca sul Cancro and by the progetto Ricerca Finalizzata awarded by the Italian Ministry of Public Health.
- 9.Bellón T, Corbi A, Lastres P, Calés C, Cebrian M, Vera S, Cheifetz S, Massagué J, Letarte M, Bernabéu C: Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol. 1993, 23: 2340-2345.CrossRefPubMedGoogle Scholar
- 12.Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A, Sedlacek HH, Müller R, Adamkiewicz J: Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer. 1999, 81: 568-572. 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O.CrossRefPubMedGoogle Scholar
- 15.Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M, Cooreman MP, Ratziu V, Langa C, Vary CP, Ramirez JR, Friedman S, Bernabeu C: Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood. 2002, 100: 4001-4010. 10.1182/blood.V100.12.4001.CrossRefPubMedGoogle Scholar
- 16.Wong SH, Hamel L, Chevalier S, Philip A: Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem. 2000, 267: 5550-5560. 10.1046/j.1432-1327.2000.01621.x.CrossRefPubMedGoogle Scholar
- 22.Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, Natali PG, Maio M: Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol. 2001, 188: 1-7. 10.1002/jcp.1095.CrossRefPubMedGoogle Scholar
- 33.Ma X, Labinaz M, Goldstein J, Millere H, Keon WJ, Letarte M, O'Brien E: Endoglin is overexpressed after arterial injury and is required for transforming growth factor-β-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol. 2000, 20: 2546-2552.CrossRefPubMedGoogle Scholar
- 37.Guerrero-Esteo M, Lastres P, Letamendia A, Perez-Alvarez MJ, Langa C, Lopez LA, Fabra A, Garcia-Pardo A, Vera S, Letarte M, Bernabeu C: Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur J Cell Biol. 1999, 78: 614-623.CrossRefPubMedGoogle Scholar
- 38.Botella LM, Sanz-Rodriguez F, Sanchez-Elsner T, Langa C, Ramirez JR, Vary C, Roughley PJ, Bernabeu C: Lumican is down-regulated in cells expressing endoglin. Evidence for an inverse correlationship between Endoglin and Lumican expression. Matrix Biol. 2004, 22: 561-572. 10.1016/j.matbio.2003.11.006.CrossRefPubMedGoogle Scholar
- 43.Ota TM, Fujii M, Sugizaki T, Ishii M, Miyazawa K, Aburatani H, Miyazono K: Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol. 2002, 193: 299-318. 10.1002/jcp.10170.CrossRefPubMedGoogle Scholar
- 49.McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, McCormick MK, Pericak-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994, 8: 345-351.CrossRefPubMedGoogle Scholar
- 50.Bourdeau A, Faughnan ME, McDonald ML, Paterson AD, Wanless IR, Letarte M: Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol. 2001, 158: 2011-2020.PubMedCentralCrossRefPubMedGoogle Scholar
- 54.Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C: Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol. 2004, 35: 176-183. 10.1016/j.humpath.2003.10.008.CrossRefPubMedGoogle Scholar
- 55.Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C: Prediction of metastasis risk [11 year follow-up] using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer [n = 905]. Br J Cancer. 2004, 90: 1216-1221. 10.1038/sj.bjc.6601452.PubMedCentralCrossRefPubMedGoogle Scholar
- 56.Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Ishikawa S, Wada H: Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesis. Lung Cancer. 2003, 39: 289-296. 10.1016/S0169-5002(02)00534-2.CrossRefPubMedGoogle Scholar
- 60.Nettelbeck DM, Miller DW, Jerome V, Zuzarte M, Watkins SJ, Hawkins RE, Muller R, Kontermann RE: Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin [CD105]. Mol Ther. 2001, 3: 882-891. 10.1006/mthe.2001.0342.CrossRefPubMedGoogle Scholar
- 62.Cowan PJ, Shinkel TA, Fisicaro N, Godwin JW, Bernabeu C, Almendro N, Rius C, Lonie AJ, Nottle MB, Wigley PL, Paizis K, Pearse MJ, d'Apice AJ: Targeting gene expression to endothelium in transgenic animals: a comparison of the human ICAM-2, PECAM-1 and endoglin promoters. Xenotransplantation. 2003, 10: 223-231.CrossRefPubMedGoogle Scholar
- 66.Costello B, Li C, Duff S, Butterworth D, Khan A, Perkins M, Owens S, Al-Mowallad AF, O'Dwyer S, Kumar S: Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int J Cancer. 2004, 109: 436-441. 10.1002/ijc.11699.CrossRefPubMedGoogle Scholar
- 70.Takahashi N, Haba A, Matsuno F, Seon BK: Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin [CD105] monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 2001, 61: 7846-7854.PubMedGoogle Scholar
- 76.Dales JP, Garcia S, Bonnier P, Duffaud F, Andrac-Meyer L, Ramuz O, Lavaut MN, Allasia C, Charpin C: CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol. 2003, 119: 374-380.CrossRefPubMedGoogle Scholar
- 78.Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S: Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer. 2003, 88: 1424-1431. 10.1038/sj.bjc.6600874.PubMedCentralCrossRefPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.